- Avalyn, in pursuit of better lung drugs, banks $300M in an IPO<figure><div><img src="https://imgproxy.divecdn.com/ok5MPeEmVJIiNJX2QcG0yjZjnAkPtgyl-6RiUb3-HFc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDUwNzUwNzQzLmpwZ…BioPharma Dive · 2mo ago↗ source
- Teva nabs experimental Tourette drug in $700M Emalex buyout<figure><div><img src="https://imgproxy.divecdn.com/bwllu2QfXYXCPlQsIYj80q37DcoRrBziEtJHydanHtM/g:nowe:0:157/c:1000:565/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90Xz…BioPharma Dive · 2mo ago↗ source
- Chiesi to buy KalVista in $1.9B deal for rare disease drug<p>The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary a…